Forest Will Delay Nebivolol NDA For CHF Pending FDA Review Of Hypertension Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is currently wrapping up pharmacokinetic studies needed to respond to an “approvable” letter for hypertension NDA.